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Background: Long-term management of chronic conditions, such as atrial fibrillation (AF), require frequent
interactions with the healthcare systems. The multinational EUropean Patient Survey in Atrial Fibrillation (EUPS-AF)
was conducted to investigate patient satisfaction with AF management in different of five European healthcare
systems at a time of changing treatment paradigms for stroke prophylaxis, prior to the advent of newer oral
anticoagulants.
Methods: Adults (>18 years) were recruited at random from the total populations of France, Germany, Italy, Spain
and the UK using a randomized telephone dialling system. At least 300 respondents per country reporting to have
a diagnosis of AF or receiving oral anticoagulation therapy for suspected AF or to have a heart rhythm disturbance
completed a structured telephone interview.
Results: Most respondents were satisfied with their treatment for AF over the previous 12 months, with 85.5%
(n = 1289) rating their care as good or better. Suboptimal clinical practices, however, were identified in several key
areas. Coordination of primary and secondary care and a lack of patient engagement and support were particular
issues, especially for those patients likely to have extensive contact with their healthcare system.
Conclusions: In the context of Europe-wide guidelines for management of AF, most patients with AF were satisfied
with their care, but for a greater proportion of patients, some aspects are unsatisfactory. Patient-centred surveys,
such as the EUPS-AF, are crucial for understanding the factors that contribute to patient satisfaction and compliance
with long-term treatment for chronic conditions.
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Atrial fibrillation (AF) is the most common cardiac rhythm
disorder, with a prevalence of between 1% and 2% in the gen-
eral population [1,2]. AF affects approximately 6 million indi-
viduals in Europe and is anticipated to double in prevalence
over the next 50 years as the population ages [1]. Patients
with AF typically require long-term management, including
anticoagulation, to prevent debilitating clinical sequelae, such
as stroke and heart failure, [1,3] costing European healthcare
systems up to €13.5 billion per annum [3].
Due to the complex nature of AF and the associated
management pathway, patients typically have extensive* Correspondence: abakhai@nhs.net
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reproduction in any medium, provided the orcontact with healthcare providers, and thus require a high
level of communication and engagement to achieve opti-
mal treatment outcomes and satisfaction with treatment.
According to the Institute of Medicine’s report in 2001, fo-
cusing on the needs of patients should be central to all
healthcare provision [4]. Understanding patient attitudes
to, and preferences for, treatment of chronic conditions is
therefore crucial for optimizing healthcare strategies [5].
However, a survey of almost 10,000 patients in eight coun-
tries worldwide has shown that management of patients
with chronic conditions is poorly coordinated and that
there is a suboptimal level of satisfaction with the standard
of care provided [6].
AF serves as a model of how healthcare resources can
be organized to optimize long-term treatment of chronic
conditions to prevent or delay the need for acuteLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 EUropean Patient Survey in Atrial Fibrillation (EUPS-AF)
questions encompassed nine domains relating to atrial fibrillation
management.
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patient satisfaction with treatment of AF is limited, with
much of the published information focusing on examin-
ing patient attitudes towards anticoagulation therapy, for
example, [7,8] rather than on the patient experience as a
whole. Moreover, patient surveys are rarely randomized,
and thus the results must be interpreted in light of po-
tential sampling bias.
The EUropean Patient Survey in Atrial Fibrillation
(EUPS-AF) was conducted to assess patient satisfaction
with the management of AF in France, Germany, Italy,
Spain, and the UK, and to identify areas in which care
could be improved, thereby providing an evidence-based
platform for optimizing patient-centred care. The survey
was conducted prior to the approval and widespread up-
take of novel oral anticoagulants, the direct thrombin and
factor Xa inhibitors that have the benefit of not requiring
anticoagulation testing. It represents therefore a unique
opportunity to establish patient preferences for AF man-
agement as we move into a new era of clinical practice.
Here, we use the rigorous Commonwealth Fund Sur-
vey methodology, which has been used widely to assess
the level of satisfaction with long-term treatment of
chronically ill patients, [6,9,10] to highlight areas where
healthcare improvements should be targeted to facilitate
patient engagement and increase patient satisfaction
with AF management.
Methods
The EUPS-AF was based on a survey developed by the
Commonwealth Fund to analyse patient attitudes to, and
satisfaction with, treatment for chronic conditions, with
focus on access to appropriate healthcare, coordination
of services, and safety [6]. In addition to the Common-
wealth Fund Survey questions, the EUPS-AF included
questions pertinent to patients receiving treatment for
AF developed by a steering group comprising clinicians
and health economists, in order to better characterize
the current population.
The authors declare, that the survey referred to in this
manuscript was not involving any biomedical research in-
volving human subjects, and that no such research have
been performed nor used in the course of the survey.
Participants
Structured telephone interviews were carried out to iden-
tify individuals older than 18 years who either responded
positively to have a diagnosis of AF or where not sure but
responded that they were receiving oral anticoagulation
therapy for either suspected AF or a heart rhythm disturb-
ance, from a random population of individuals with a tele-
phone landline in France, Germany, Italy, Spain and the
UK. The sample was stratified with random sampling con-
ducted within a stratum made up of the five countries.The sample size and power of the survey were pragmatic,
consisting of approximately 300 participants per country.
Survey methodology
After a pilot survey involving 152 respondents con-
ducted in February and March 2011, the questionnaire
was adapted minimally to explain more clearly some
medical terms associated with AF and to remind re-
spondents to base their answers specifically on their ex-
periences of AF management. The main survey was
conducted between 1 May and 18 July 2011. Overall,
1507 individuals were surveyed, including those taking
part in the pilot survey.
Questionnaire
Interviews based on the questionnaire [see Additional
file 1], with verified translations into local languages,
were conducted by telephone using a computer-assisted
telephone interview (CATI) technique [11]. Eligible indi-
viduals agreeing to participate in the survey were then
asked a series of questions concerning levels of satisfac-
tion with healthcare provision in nine domains (Figure 1).
A large amount of data was collected under each do-
main, and in the current paper, results from various do-
mains are being presented, with the common focus on
healthcare improvement, patient engagement and pa-
tient satisfaction with AF management.
Participants were not provided with any incentives to
participate in the survey. The survey did not require eth-
ical review but, before each interview, respondents were
informed about the purpose of data collection and pro-
vided their verbal consent to participate in the survey
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that they could terminate the interview at any point.
Assessment of stroke risk
The CHADS2 (Congestive heart failure, Hypertension,
Age, Diabetes, prior Stroke) scoring system calculates
the annual risk of stroke based on whether a patient has
congestive heart failure, hypertension (blood pressure
consistently ≥140/90 mm Hg), is aged at least 75 years
or more, has diabetes mellitus, or has a prior history of
stroke or transient ischemic attack. Physicians use this
information to assess the risk–benefit ratio for adminis-
tering anticoagulation therapy for stroke prevention in
patients with AF [1]. Participants were stratified into
those at low, medium, and high risk of stroke (scores of
0, 1–2 or >2, respectively).
Data analysis
For quantitative parameters, summary statistics, mean ±
standard deviation are reported. For qualitative and or-
dinal parameters, the number of patients within a spe-
cific category are presented as absolute and percentage
numbers [n (%)], using the total number of patients as
denominator (N). Missing values are considered as a
valid category ‘no response’.
Results
Response rate and participant characteristics
In total, 568,339 telephone numbers were randomly gen-
erated, and a total of 340,476 numbers were dialled in
order to obtain the minimum of 300 participants with AF
per country. Of the 1828 individuals contacted who met
the EUPS-AF inclusion criteria, 321 declined to participate
in the survey. The average duration of the telephone inter-
views was 39 minutes (range, 16–151 minutes).
Respondent characteristics are shown in Table 1. Mean
age was 70.1 ± 12.5 years (range, was 70.1 ± 12.5 years
(range, 68.5–70.8 years) with approximately equal num-
bers of men and women. Respondent characteristics
were generally well matched across countries in terms of
age, sex, CHADS2 score, and comorbidities.
Patient opinion on their healthcare system
Participants were asked to provide an opinion on their
national healthcare system by selecting one of the fol-
lowing statements: “on the whole the system works
pretty well, and only minor changes are necessary to
make it work better”, “there are some good things in our
healthcare system, but fundamental changes are needed
to make it work better”, “our healthcare system has so
much wrong with it that we need to completely rebuild
it”. Overall, 44.7% (n = 673) thought that their national
healthcare system worked ‘pretty well’ and that only
minor changes were necessary to make it work better.Patients in the UK were more likely to declare this state-
ment to be true (54.7% positive responses [n = 164]) than
patients in France, Germany, Italy, or Spain (range, 37.1 –
46.9% [n = 112–143]). Patients in the UK were also less
likely to state that their healthcare system had so much
wrong with it that it needed rebuilding completely (3.7%
[n = 11]) in comparison to the other four surveyed coun-
tries (range, 11.0 – 17.5% [n = 33–53]).
Patient satisfaction with quality of care
Participants were asked to rate the quality of care they had
received in the previous 12 months using a five-point
Likert scale (excellent, very good, good, fair or poor). Over-
all, 85.5% of respondents (n = 1289) rated the quality of
care they had received in the previous 12 months as good,
very good, or excellent (range, 71.5 – 91.7% [n = 216 –
275]) (Figure 2a). Respondents in Germany, the UK, and
France were more likely to report care that was good, very
good, or excellent (Germany, 90.7% [n = 272] of partici-
pants; UK, 91.7% [n = 275]; France, 89.7% [n = 269]) than
were individuals in Italy or Spain (71.5% [n = 216] and
84.3% [n = 257], respectively). Dissatisfaction with medical
care was higher in Italy (26.8% [n = 81] rated care as fair or
poor) than in the other four countries surveyed (range,
6.7–14.8% [n = 20–45]).
The overall rating of quality of care did not differ sub-
stantially between men and women, or between different
age groups (Figure 2b).
Coordination of care
The proportion of patients who had seen a specialist dur-
ing the previous 2 years varied across countries. In France,
patients were more likely to have seen a specialist than in
the other countries surveyed (89.7% [n = 269] vs. 68.3 –
78.3% [n = 205–238]). Moreover, waiting times to see a
specialist varied widely, from an average of 4.0 weeks in
Germany to 11.9 weeks in Spain; 40.8% (n = 97) of Spanish
respondents had to wait for more than 8 weeks to see a
specialist, a higher proportion than in the other countries
surveyed (range, 16.7–25.9% [n = 43–54]). Patients with
the highest CHADS2 score (score 5–6) had to wait an
average of 7.8 weeks to see a specialist, longer than pa-
tients with lower CHADS2 scores (range, 4.4–7.2 weeks).
Patients with high CHADS2 scores (score 5–6) re-
ported the most problems with coordination of care.
More patients in this group felt that they had been rec-
ommended treatment that had little health benefit (22%)
than did patients with lower scores (CHADS2 score, 0–4;
range, 15–20%). A greater proportion of patients (16%)
with high CHADS2 scores thought that medical tests had
been performed unnecessarily, compared with lower
CHADS2 scores (range, 9–13%).
Overall, 79.3% of respondents (n = 1195) had seen more
than one doctor during the previous 2 years for the same
Table 1 Demographic characteristics of the EUropean patient survey in Atrial Fibrillation respondents*
France
(N = 300)
Germany
(N = 300)
Italy
(N = 302)
Spain
(N = 305)
UK
(N = 300)
Total
(N = 1507)
Mean age, years (SD) 68.5 (13.7) 70.4 (10.5) 70.8 (12.2) 70.8 (13.7) 70.3 (11.9) 70.1 (12.5)
<50 years, n (%) 22 (7.3) 17 (5.7) 19 (6.3) 24 (7.9) 20 (6.7) 102 (6.8)
50– < 65 years, n (%) 91 (30.3) 55 (18.3) 57 (18.9) 54 (17.7) 65 (21.7) 322 (21.4)
≥65 years, n (%) 187 (62.3) 228 (76.0) 226 (74.8) 227 (74.4) 215 (71.7) 1083 (71.9)
Male, n (%) 153 (51.0) 154 (51.3) 152 (50.3) 138 (45.2) 153 (51.0) 750 (49.8)
Receiving oral anticoagulation n (%)**
Yes 215 (71.7) 232 (77.3) 224 (74.2) 253 (83.0) 231 (77.0) 1155 (76.6)
No 54 (18.0) 37 (12.3) 36 (11.9) 24 (7.9) 36 (12.0) 187 (12.4)
No response 6 (2.0) 2 (0.7) 13 (4.3) 5 (1.6) 4 (1.3) 30 (2.0)
Not asked 25 (8.3) 29 (9.7) 29 (9.6) 23 (7.5) 29 (9.7) 135 (9.0)
Income, n (%)
Below average 156 (52.0) 175 (58.3) 169 (56.0) 196 (64.3) 154 (51.3) 850 (56.4)
Average 65 (21.7) 37 (12.3) 90 (29.8) 42 (13.8) 59 (19.7) 293 (19.4)
Above average 50 (16.7) 53 (17.7) 16 (5.3) 23 (7.5) 57 (19.0) 199 (13.2)
No response 29 (9.7) 35 (11.7) 27 (8.9) 34 (14.4) 30 (10.0) 165 (10.9)
CHADS2 score, n (%)
0 10 (3.3) 9 (3.0) 10 (3.3) 10 (3.3) 6 (2.0) 45 (3.0)
1–2 74 (24.7) 83 (27.7) 68 (22.5) 70 (23.0) 82 (27.3) 377 (25.0)
>2 216 (72.0) 208 (69.3) 224 (74.2) 225 (73.8) 212 (70.7) 1085 (72.0)
Number of current medications
Mean (SD) 5.7 (4.1) 5.4 (4.0) 5.4 (3.3) 6.0 (3.9) 6.1 (4.1) 5.7 (3.9)
>10 medications, n (%) 46 (15.3) 26 (8.7) 34 (11.3) 45 (14.8) 48 (16.0) 199 (13.2)
Where respondents live, n (%)
City/large town 99 (33.0) 76 (25.3) 45 (14.9) 138 (45.2) 105 (35.0) 463 (30.7)
Small town 87 (29.0) 92 (30.7) 90 (29.8) 28 (9.2) 89 (29.7) 386 (25.6)
Village/rural location 113 (37.7) 130 (43.3) 165 (54.6) 138 (45.2) 105 (35.0) 651 (43.2)
No response 1 (0.33) 2 (0.67) 2 (0.66) 1 (0.33) 1 (0.33) 7 (0.46)
Comorbidities, n (%)
Mean 2.1 2.1 2.2 2.3 2.3 2.2
Hypertension 152 (50.7) 208 (69.3) 197 (65.2) 180 (59.0) 185 (61.7) 922 (61.2)
Heart disease 165 (55.0) 167 (55.7) 130 (43.0) 141 (46.2) 135 (45.0) 738 (49.0)
Diabetes 60 (20.0) 78 (26.0) 60 (19.9) 68 (22.3) 50 (16.7) 316 (21.0)
Arthritis 69 (23.0) 47 (15.7) 127 (42.1) 103 (33.8) 144 (48.0) 490 (32.5)
Asthma, COPD, or other chronic lung disease 55 (18.3) 53 (17.7) 48 (15.9) 63 (20.7) 49 (16.3) 268 (17.8)
Depression, anxiety, or other mental health problem 90 (30.0) 47 (15.7) 75 (24.8) 126 (41.3) 77 (25.7) 415 (27.5)
Cancer 39 (13.0) 43 (14.3) 31 (10.3) 34 (11.1) 40 (13.3) 187 (12.4)
Stroke 78 (26.0) 31 (10.3) 59 (19.5) 63 (20.7) 95 (31.7) 326 (21.6)
*These data were patient-reported and were not confirmed by a treating clinician.
**This question was added to the survey during the pilot phase of the survey and therefore not all respondents were asked.
AF = atrial fibrillation; CHADS = congestive heart failure, hypertension, age, diabetes, prior stroke; COPD = chronic obstructive pulmonary disease;
SD = standard deviation.
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continuity in care (Figure 3a). There were differences be-
tween countries in how informed patients felt that theirregular doctor was about the care the patient received
from the specialist they had been seeing. In France, only
4.0% (n = 10) of patients felt that their regular doctor was
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Figure 2 Patient rating of quality of medical care. (a) Patient
rating of quality of medical care received during the previous 12
months and (b) overall rating of quality of care by age and sex.
Survey question: Overall, how do you rate the quality of medical
care that you have received in the past 12 months?
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Figure 3 Medical care organization. (a) Number of general
practitioners or specialists seen by patients during the previous 2
years and (b) proportion of patients who believed that their time
had been wasted due to poorly organized care during the previous
2 years. Survey questions: (a) How many different doctors have you
seen in the past 2 years, including your regular doctor (the doctor
you rely on most for your care) and any specialist doctors or
consultants? (b) In the past 2 years, how often did you feel your
time was wasted because your medical care was poorly organized?
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tion, while in Italy and Spain this figure was higher (28.3%
[n = 41] and 26.7% [n = 50], respectively). Many patients
felt that their time had often, or occasionally, been wasted
because care was poorly organized (Figure 3b). In Italy,
18.2% (n = 55) of respondents felt that their time had often
been wasted due to poor coordination, a greater propor-
tion than in the other countries surveyed (range, 3.0–
11.5%, [n = 9–35]). Women were more likely than men to
feel that their time had been wasted (10.8% [n = 82] vs.7.3% [n = 55]). Neither income nor age affected the per-
ception of wasted time.
Current medications
Prescription medication use
On average, respondents were taking approximately six
prescription medications on a regular basis, and 13.2%
(n = 199) of patients were taking 10 or more prescription
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http://www.biomedcentral.com/1471-2261/13/108medications (range, 8.7–16.0% [n = 26–48]) (Figure 4).
In total, 80.7% (n = 918) of patients expressed a prefer-
ence for taking anticoagulation medication once daily
compared with only 7.6% (n = 87) who preferred a twice-
daily regimen.
Differences in the extent to which doctors or pharma-
cists engaged with patients to review their medication
were observed between countries (Figure 4). A greater
proportion of respondents in Italy rarely or never had
their medication reviewed compared with the other
countries surveyed (71.8% [n = 209] vs. 29.2–47.4%, [n =
84–136]). Moreover, a greater proportion of patients in
Spain always had their medication reviewed (41.0%, n =
118) than in the other four European countries (range,
4.8–27.5% [n = 14–80]).
The proportion of patients who had been informed of
the potential side effects of their medication was low in
all the countries surveyed (mean, 14.6% [n = 212] of re-
spondents; range, 8.9–30.3% [n = 26–87]). A greater pro-
portion of patients in France had been informed about
potential medication side effects when filling a prescrip-
tion (30.3%, n = 87) compared with their European coun-
terparts (range, 8.9–11.7%) [n = 26–35].
Anticoagulation testing
Differences in approaches towards anticoagulation test-
ing to determine patients’ international normalized ratio
(INR) values were observed among countries (Figure 5).0
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Figure 4 Frequency with which medications were reviewed by
doctors or pharmacists during the previous 2 years. Survey
question: In the past 2 years, how often have any of your doctors or
your pharmacists reviewed and discussed all the different
medications you are using, including medicines prescribed by
other doctors?
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Figure 5 Anticoagulation testing. (a) Settings for anticoagulation
testing and (b) attitudes to no longer needing regular
anticoagulation testing. Survey questions: (a) Where is your PT/INR
monitored? (b) What do you think about the possibility of no longer
having the need to get coagulation test done like PT/INR? GP =
general practitioner; INR = international normalized ratio;
PT = prothrombin time.A greater proportion of French patients with AF received
regular anticoagulation testing (71.5%, n = 211) than was
reported for other countries (range, 46.1–60.9% [n = 137–
182]), with more than half of tests taking place in a local,
specialized laboratory. Conversely, Italian respondents
were not only less likely to receive regular anticoagulation
testing than their French counterparts (57.3%, [n = 172]
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to a hospital for testing (63.4%, n = 109) than respondents
from any of the other European countries surveyed (range,
2.2–33.3% [n = 4–55]).
Healthcare systems differed in the setting in which pa-
tients received anticoagulation testing (Figure 5a). In
Germany, more respondents (82.4%, n = 150) received
anticoagulation testing at their local doctor’s surgery
than in the other European countries (range, 7.6–53.3%
[n = 13–88]). Overall, just 2.5% of respondents (n = 22)
self-administered their anticoagulation test at home,
prevalent only in Germany and Italy, 5.5% (n = 10) and
5.2% (n = 9), respectively. Patients in France were more
likely to have their anticoagulation test performed at
home by a district nurse (21.3% [n = 45]) than in the
other European countries (range, 1.6–5.1% [n = 3–7]).
Italian respondents were the most positive about the
benefit of reduced anticoagulation testing (77.9% [n = 120]
positive responses) (Figure 5b). Individuals in France and
Germany were less positive about a reduction in monitor-
ing requirements (49.0% [n = 97] and 47.5% [n = 77] posi-
tive responses, respectively) than patients in Italy, Spain,
and the UK (range, 63.8–77.9% [n = 95–120]).
Across all countries surveyed, 28.0% (n = 134) of respon-
dents would favour reduced anticoagulation testing be-
cause of the time saved, while 29.0% (n = 139) cited the
reason as a reduction in the need to travel regularly to an
appropriate testing centre. Of those respondents not in
favour of reduced testing (mean, 25.2% [n = 199]; range,
11.7–39.5% [n = 18–64]), many were either concerned
about the uncertainty of not knowing their anticoagulation
status (mean, 31.7% [n = 63]; range, 17.6–45.3% [n = 3–
29]) or felt that they needed to know their INR value
(mean, 41.7% [n = 83]; range, 22.2–53.7% [4–22]).
Discussion
The multinational EUPS-AF highlights international
differences in the management of patients with AF despite
Europe-wide treatment guidelines, in particular widely
varying service delivery of therapies such as anticoagula-
tion. Although the majority of patients are satisfied with
their care, some individuals experience poorly coordi-
nated care and lack of engagement and support when
receiving treatment for this complex, chronic and bur-
densome condition.
Factors affecting patient satisfaction
Management of patients with AF, many of whom has one
or more comorbidities and frequently receives several pre-
scriptions, is often complex and burdensome, leaving
some patients vulnerable to miscommunication, lack of
engagement, and reduced coordination of care. Medica-
tion reviews, education and access to self-testing therapies,
providing some autonomy to the patients, is variable andlimited. In this regard, novel oral anticoagulants that do
not require patients to undertake regular anticoagulation
monitoring and dose adjustment may improve patient sat-
isfaction with management. Differences in attitudes to-
wards anticoagulation testing among countries, however,
indicate that doctors should carefully consider patients’
anticoagulation preferences. In France and Germany,
many of those patients not in favour of transitioning to
new oral anticoagulants cited the peace of mind that regu-
lar consultations for anticoagulation testing with health-
care professionals provide, highlighting that less contact
with doctors is not always a desirable outcome for pa-
tients. Moreover, it is tempting to speculate that the rela-
tive convenience of anticoagulation testing in France and
Germany, in a local laboratory or doctors’ practice, results
in less enthusiasm towards the reduced need for regular
anticoagulation testing with novel anticoagulants. In the
UK, Spain, and Italy, where testing is less convenient than
in France or Germany, and therefore poses a greater bur-
den to patients, a higher proportion of respondents were
in favour of reduced monitoring. Thus the EUPS-AF re-
sults suggest that the convenience and location of anticoa-
gulation testing may contribute to patients’ attitudes
towards regular monitoring.
Access to healthcare
Where patients live, and how far they have to travel for
consultation and monitoring, is also likely to contribute
substantially to their satisfaction with AF management.
Respondents in Italy were more likely to report to live in
rural areas than respondents from other countries, and
therefore also more likely to have to travel to see a spe-
cialist in hospital to receive their care. The impact of
such a patient burden on their attitude to, and satisfac-
tion with, their care should not be underestimated and
reflects an important economic consideration. Many pa-
tients with AF are elderly and thus may have difficulty
travelling to hospital clinics to have their anticoagulation
status monitored on a regular basis.
Coordination of care
Receiving healthcare through multiple sources can in-
crease the risk of reduced coordination of care; for ex-
ample, through miscommunication between primary and
secondary care. Almost one-third of patients in Italy and
Spain felt that their regular doctor was not well in-
formed about the care they had received from special-
ists, compared with only 4% of patients in France.
Waiting times were longest in the UK and Spain, where
access to secondary care has been a long-standing issue
for policymakers, while patients in Germany experienced
the shortest waiting times to see a specialist. Despite al-
most half of respondents from Spain more often review-
ing their medication with their doctor, they were no
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medications than patients who reviewed their medica-
tion less often with health care professionals. Moreover,
the present survey indicates that there is still a need for
education for patients about their anticoagulation treat-
ment, especially referring to the proportion of patients
with high CHADS2 scores, feeling that they had been
recommended treatment with little health benefit and
that medical tests had been performed unnecessarily.
EUPS-AF results in context
Results from the EUPS-AF confirm findings from the
Commonwealth Fund Survey that improvements in
healthcare systems need to be implemented to increase
patient satisfaction and compliance with long-term treat-
ment of chronic conditions, [6,10] and to comply with
the guidelines on AF management [1]. While both the
EUPS-AF and Commonwealth Fund Survey demon-
strated broad differences in levels of satisfaction across
countries, it is particularly notable that both surveys
identified that levels of satisfaction were higher in the
UK than in other countries. This may reflect initiatives
in the UK in the past 5 years to improve delivery and co-
ordination of healthcare to patients with chronic condi-
tions. Differences between countries may also be due to
cultural differences. Another factor to be taken into ac-
count when interpreting the results of EUPS-AF is the
effect on the healthcare systems that the economic crisis
may have [12-14].
Initiatives from patient support groups, such as the Atrial
Fibrillation Association, [15] and recent European guide-
lines on the prevention of cardiovascular disease, [16] fur-
ther highlight an increasing awareness of patient-centred
care for cardiac conditions. Moving towards healthcare
pathways within which patients are able to exert some con-
trol over their management is a key goal in increasing satis-
faction with treatment, and thus outcomes, in patients
with a wide range of conditions [17,18].
A lack of patient engagement in managing stroke
prophylaxis has previously been highlighted as an issue by
Aliot and colleagues, who suggested that patients should
be allowed to make informed decisions about their treat-
ment [19]. Evidence shows that patients with AF appear to
place more value on avoiding stroke and subsequent
hospitalization than their physicians, who appear more
concerned with the risk of haemorrhage, [19,20] further
emphasizes the need for patients to be involved in treat-
ment decisions. Moreover, MacLean and colleagues have
recently observed that previous patient experience sub-
stantially impacts on treatment preferences [7]. A system-
atic review of stroke prophylaxis in patients with AF
revealed substantial heterogeneity in patient treatment
preferences, and the review emphasized that patients
should be assessed and treated on an individual basis [7].Engagement and communication with patients, including
providing sufficient information and support for them to
participate in management decisions, should be a key con-
sideration for healthcare professionals.
To the best of our knowledge, the EUPS-AF represents
the largest ever survey of patient satisfaction with AF
management. Unlike previous surveys, which have gen-
erally focused on patient and physician attitudes towards
anticoagulation alone, the EUPS-AF survey highlights
patient attitudes towards, and satisfaction with, AF man-
agement as a whole, in the context of national healthcare
systems. Furthermore, the countries surveyed were
chosen to represent a diverse range of healthcare sys-
tems from those that have adopted the unified guidance
framework for AF management [1].
The EUPS-AF demonstrates that it is possible to adapt
the rigorous Commonwealth Fund methodology to as-
sess differences in patient satisfaction with treatment for
a specific chronic condition. Randomized telephone dial-
ling reduced the selection bias often associated with pa-
tient surveys, and ensured that a representative range of
patients with AF was included.
The survey does have a number of limitations. Despite
the randomized selection protocol, there is potential for
selection bias given that only those who were willing to
take the time to respond to the calls were included in
the survey. Moreover, the computer-assisted telephone
interviewing technique is inherently biased towards
those individuals with static telephone lines, excluding
individuals without a permanent landline. Regional vari-
ance in telephone access amongst countries was not
accounted for. The biases of a primary care only popula-
tion or of patients with reasonable mobility to undertake
research were however minimized by randomly detect-
ing these patients by telephone. The sample size was
pragmatic, and the precision of patient characteristics
and power to detect level of difference between coun-
tries were not taken into account when planning the
sample size. For country differences, no weighting of the
results in relation to difference in prevalence between
countries has been used. The survey did not address sur-
gical interventions for the management of AF or explore
the influence of alternative rate control therapies, such as
the ‘pill-in-a-pocket’ strategy, on patient satisfaction. Source
data relied fully on patient volunteered responses and out-
comes, and was neither verified with their treating physi-
cians, nor weighted for differences in living environment,
age or type of AF (paroxysmal, persistent or permanent).
Since the time of data collection, the recommendation of
scoring of the European Society of Cardiology guidelines
on the management of AF had changed from CHADS2 to
CHADS2VASc and this was not taken into account in the
current data analysis [21]. CHADS2VASc gives a better
stratification of low-risk patients.
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Patient satisfaction with treatment is a key component of
the successful management of chronic conditions such as
AF. Management of AF patients in real-world practice
shows considerable variation and is often not consistent
with current recommendations, and the survey supports
the need to include aspects of patient-centred care in
treatment guidelines. The survey also identified key areas
where healthcare systems can improve in order to
optimize patient satisfaction with AF management, includ-
ing increasing patient education and engagement, service
delivery models and coordination of care.
Moreover, the survey highlights satisfaction with AF
management during the key period before novel anticoag-
ulants enter regular clinical practice, thus providing a
snapshot of AF management at a time of changing treat-
ment paradigms. Further research will be required to as-
sess the impact of the introduction of novel anticoagulants
on satisfaction of patients with AF management and to
identify the best method of adopting a patient perspective
into AF management strategies.
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